Sarcopenia Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The sarcopenia treatment market size has grown strongly in recent years. It will grow from $3.52 billion in 2024 to $3.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to aging population, awareness and diagnosis, lifestyle changes, public health initiatives, regulatory approvals.

The sarcopenia treatment market size is expected to see strong growth in the next few years. It will grow to $4.72 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to personalized medicine, nutritional interventions, digital health platforms, patient education and empowerment, global health initiatives. Major trends in the forecast period include personalized therapies, emergence of novel drug classes, digital health integration, collaborative research initiatives, research and development.

The anticipated increase in malnutrition is poised to drive the growth of the sarcopenia treatment market in the future. Malnutrition encompasses deficiencies, excesses, or imbalances in an individual's intake of energy and nutrients, including both undernutrition and overweight, obesity, and diet-related noncommunicable diseases. Sarcopenia treatment plays a crucial role in addressing the concurrent conditions of malnutrition and sarcopenia in older adults through interventions such as nutritional therapy and exercise, with the aim of enhancing muscle mass, strength, and overall nutritional status. For instance, a report published by the World Health Organization (WHO) in December 2023 highlighted malnutrition as a significant global health challenge, with an estimated 462 million underweight individuals and 149 million children under 5 experiencing stunting in 2022. Consequently, the surge in malnutrition acts as a driving force behind the growth of the sarcopenia treatment market.

Major companies in the sarcopenia treatment market are intensifying their focus on developing multiple advanced clinical studies to enhance treatment options. A clinical study involves a systematic investigation conducted on human subjects to assess the safety, efficacy, and/or outcomes of a medical intervention. For instance, in September 2023, Biophytis, a France-based biotechnology company, disclosed the authorization from the Food and Drug Administration (FDA) to commence the SARA-31 Phase 3 study in sarcopenia. This study aims to assess the efficacy and safety of Sarconeos (BIO101) in treating sarcopenic patients at risk of motor disability. Representing a significant advancement in technological and pharmaceutical treatment modalities, this study offers potential benefits in terms of efficacy and safety for severe sarcopenic patients. Notably, it marks the first-ever Phase 3 study in sarcopenia to receive FDA authorization. The study will involve approximately 900 patients aged over 65 with sarcopenia, low walking speed, and low hand grip strength. The primary endpoints will include the evaluation of the risk of major mobility disability (MMD), walking speed, hand grip strength, and patient-reported quality of life.

In August 2023, Eli Lilly and Company, a pharmaceutical company based in the US, acquired Versanis Bio in a deal valued at $1.925 billion. Through this acquisition, Lilly’s portfolio now includes Versanis’ key asset, bimagrumab. This drug is currently in a Phase 2b clinical study, being tested both as a standalone treatment and in combination with semaglutide for adults with overweight or obesity. Versanis Bio is a biotechnology company in the US focused on developing treatments for sarcopenia.

Major companies operating in the sarcopenia treatment market report are Pfizer Inc., F-Hoffmann La-Roche, Merck Sharp & Dohme Corp. (Merck & Co.), AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Eli Lilly and Company, BASF SE, Nestle Health Science, Haleon Group of Companies, Regeneron Pharmaceuticals Inc., DSM, American Way (Amway) Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Ion Labs Inc., Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt. Ltd., Nutrafill.

North America was the largest region in the sarcopenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sarcopenia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sarcopenia treatment market consists of revenues earned by entities by providing nutritional therapy, combination therapy, and muscle strength. The market value includes the value of related goods sold by the service provider or included within the service offering. The sarcopenia market also includes sales of muscle stimulators, orthopedic braces and supports, joint replacement implants, anabolic agents, and more. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Sarcopenia treatment encompasses medical interventions and lifestyle strategies tailored to counteract age-related muscle loss, aiming to preserve or enhance skeletal muscle mass and function. The goal of treatment is to mitigate age-related muscle decline, bolster muscle strength, and improve overall physical function and mobility.

The main types of sarcopenia treatments include protein supplements, vitamin B12 supplements, vitamin D and calcium supplements, and others. Protein supplements, available in forms such as bars, powders, or shakes derived from whey, plant, or meat sources, are utilized for both primary and secondary sarcopenia treatment and can be administered orally, parenterally, or enterally. These supplements are distributed through various channels including hospital pharmacies, retail pharmacies, and online pharmacies.

The sarcopenia treatment market research report is one of a series of new reports that provides sarcopenia treatment market statistics, including sarcopenia treatment industry global market size, regional shares, competitors with a sarcopenia treatment market share, detailed sarcopenia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sarcopenia treatment industry. This sarcopenia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.